FDA OK's Gilead's 'TAF' Combo HIV Drug Odefsey
This article was originally published in Scrip
Executive Summary
Gilead Sciences Inc. on March 1 gained the FDA's approval to market Odefsey as a treatment for HIV-1 infection – the second so-called TAF-based regimen to win the agency's OK.